Kyntra Bio/$KYNB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kyntra Bio
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Ticker
$KYNB
Sector
Primary listing
Employees
225
Headquarters
Website
Kyntra Bio Metrics
BasicAdvanced
$29M
0.14
$53.38
0.75
-
Price and volume
Market cap
$29M
Beta
0.75
52-week high
$12.60
52-week low
$4.85
Average daily volume
33K
Financial strength
Current ratio
3.709
Quick ratio
3.561
Long term debt to equity
111.358
Total debt to equity
111.358
Interest coverage (TTM)
-6.91%
Profitability
EBITDA (TTM)
-58.064
Gross margin (TTM)
-365.76%
Net profit margin (TTM)
2,598.87%
Operating margin (TTM)
-712.89%
Effective tax rate (TTM)
0.17%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-18.42%
Return on equity (TTM)
56.74%
Valuation
Price to earnings (TTM)
0.136
Price to revenue (TTM)
3.54
Price to book
-1.73
Price to tangible book (TTM)
-1.73
Price to free cash flow (TTM)
-1.718
Free cash flow yield (TTM)
-58.19%
Free cash flow per share (TTM)
-4.23
Growth
Revenue change (TTM)
-117.53%
Earnings per share change (TTM)
-274.36%
3-year revenue growth (CAGR)
-59.28%
10-year revenue growth (CAGR)
-26.17%
3-year earnings per share growth (CAGR)
-18.04%
10-year earnings per share growth (CAGR)
3.04%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kyntra Bio stock?
Kyntra Bio (KYNB) has a market cap of $29M as of February 26, 2026.
What is the P/E ratio for Kyntra Bio stock?
The price to earnings (P/E) ratio for Kyntra Bio (KYNB) stock is 0.14 as of February 26, 2026.
Does Kyntra Bio stock pay dividends?
No, Kyntra Bio (KYNB) stock does not pay dividends to its shareholders as of February 26, 2026.
When is the next Kyntra Bio dividend payment date?
Kyntra Bio (KYNB) stock does not pay dividends to its shareholders.
What is the beta indicator for Kyntra Bio?
Kyntra Bio (KYNB) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.